November 1, 2022
RegMed Investors’ (RMi) pre-open: the ups, the downs and the uglies i.e., share pricing
October 31, 2022
RegMed Investors’ (RMi) pre-open: final session of October
October 28, 2022
RegMed Investors’ (RMi) pre-open: what’s to deal with beforehand that might hinder sector’s progress in November?
October 27, 2022
RegMed Investors’ (RMi) pre-open: I’m anxious and fearful
October 26, 2022
RegMed Investors’ (RMi) pre-open: electronic trading and algorithmic rules keep sentiment on a leash
October 25, 2022
RegMed Investors’ (RMi) pre-open: exposure to risk never changes
October 24, 2022
RegMed Investors’ (RMi) pre-open: downshift following a volatile week
October 21, 2022
RegMed Investors’ (RMi) pre-open: climbing the ladder of share pricing
October 20, 2022
RegMed Investors’ (RMi) pre-open: weakness
October 19, 2022
RegMed Investors’ (RMi) pre-open: I’d be letting the upsiders run and then fast walk share pricing profits
October 18, 2022
RegMed Investors’ (RMi) pre-open: how many signals are needed to forecast the sector’s move
October 17, 2022
RegMed Investors’ (RMi) pre-open: earnings are the elephant in the room
October 14, 2022
RegMed Investors’ (RMi) pre-open: an absence of certainty in inflation and earnings
October 13, 2022
RegMed Investors’ (RMi) pre-open: pivot means change away or towards risks which are high while rewards are low
October 12, 2022
RegMed Investors’ (RMi) pre-open: producer price report weighs the session
October 11, 2022
RegMed Investors’ (RMi) pre-open: is a short-term bottom close – not by a long-shot?
October 10, 2022
RegMed Investors’ (RMi) pre-open: the share pricing game, musical chairs
October 7, 2022
RegMed Investors’ (RMi) pre-open: resistance and key jobs report posts the number, 263,000 with unemployment 3.5%
October 6, 2022
RegMed Investors’ (RMi) pre-open: tick, tock; where’s the price of cell and gene therapy stocks going
October 5, 2022
RegMed Investors’ (RMi) pre-open: silly question yet, will the cell and gene therapy sector outperform its daily spin?
October 4, 2022
RegMed Investors’ (RMi) pre-open: buy a few dips and a mixed bag of indications
October 3, 2022
RegMed Investors’ (RMi) pre-open: Q4 kicks off
September 30, 2022
RegMed Investors’ (RMi) pre-open: liquidity, an issue as month and Q3 close
September 29, 2022
RegMed Investors’ (RMi) pre-open: what now, after I wrote “sell into any strength”?
September 28, 2022
RegMed Investors’ (RMi) pre-open: sell into any strength as U.S. and global markets fall
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.